Daniel B. Roark, Founder and CEO

Mr. Roark is a knowledgeable entrepreneur with 19 years of experience in the life science research market. Prior to founding MatriCal, he served as the Vice President/General Manager of the Liquid Handling Business Element of PerkinElmer Life Sciences, an S&P 500 company. From 1994 until 1998, he was employed by, and then a co-owner of Carl Creative Systems, a business that he sold to Packard BioScience in 1998. PerkinElmer Life Sciences subsequently purchased Packard in 2001. He is credited with launching several innovative liquid handling instruments currently on the market as well as partnering with the major international institutes involved in the Human Genome Project which was completed in 2003. Mr. Roark obtained a B.S. in Biochemistry in 1984 from Whitworth College, Spokane, Washington, and a B.S. in Chemical Engineering in 1987 from Washington State University.

Kevin R. Oldenburg, Ph.D., Founder and President

Dr. Oldenburg received his PhD in 1990 from the Department of Chemistry and Biochemistry at UCLA where he focused on protein structure function relationships. Upon completion of his PhD, he joined Affymax as a postdoctoral fellow with Dr. Peter Schultz of U.C. Berkeley. During this time he performed some of the seminal work with "peptides on phage", demonstrating that small peptides could mimic and inhibit sugar binding to lectins. As a Staff Scientist at Affymax, he was involved in developing methods and technology for high throughput screening of combinatorial libraries. In 1996, he became the Director of Biomolecular Screening at DuPont Pharmaceuticals, where his group focused on both conventional screening as well as assay miniaturization. His group developed some of the first truly miniaturized assays in a 9600-well (0.2ul) plate. In 2000, Dr. Oldenburg left DuPont Pharmaceuticals to found MatriCal, Inc., a company focused on technology development or the Pharmaceutical Industry. Dr. Oldenburg currently holds over 20 patents issued and pending and has over 50 peer reviewed publications. In addition, he has extensive industrial experience in biotechnology, with particular expertise in the areas of assay development, high throughput screening and technology development.

Margo L. Buckles, Board Member
Margo L. Buckles formally joined MatriCal, Inc. in February 2003, where she works as corporate counsel. Before joining MatriCal, Ms. Buckles worked with the Internal Revenue Service's General Legal Services in San Francisco, California, with Pepper Hamilton LLC, in Philadelphia, Pennsylvania, and with Gallagher, Schoenfeld, Surkin & Chupein, PC, in Media, Pennsylvania. Ms. Buckles is a graduate of the University of Wisconsin - Madison (B.A., Political Science/Spanish), UCLA (M.A., Latin American Studies), and UC Hastings College of Law.

Gary Sams, PhD, Board Member

Dr. Gary Sams has worked as a Sales and Marketing executive for the last 20 years in the life sciences research and drug discovery tools sectors.

He has played pivotal roles in a broad spectrum of activities, including early corporate formation, commercial strategy development, marketing, business development, and sales at several life sciences reagents and instrumentation companies, including Promega, EG&G (now Perkin Elmer), Digene (Nasdaq: DIGE), and Vysis (acquired by Abbott for $350MM in 2002).

For the past five years Dr. Sams has provided strategic marketing and commercialization consulting services as a Managing Partner of Beachhead Consulting Group. The group's clients include a wide range of leading life science companies including Applied Biosystems, Invitrogen, Perkin Elmer, and Caliper. Dr. Sams has also worked with many early-stage companies, including Geneospectra, 454 Corporation, Cytokinetics, Sequenom, and Nanogen.

Dr. Sams has broad experience in technologies, from genomics to proteomics to cell assays. He has worked in virtually all product platforms including reagents, instruments, and imaging systems, and has worked in evaluating all parts of the drug discovery process, from basic research through drug discovery and development.

Prior to entering the commercial sector, Dr. Sams received his Ph.D. in Cell Biology from the University of Kansas and completed a post-doctoral fellowship in Cancer Molecular Biology at the University of Wisconsin.

Thomas C. Tisone, Ph.D., Board Member

Thomas C. Tisone, Ph.D., 64 is currently President of Biodot, Inc. a company that supplies sub microliter dispensing technology to the diagnostics industry. He was a co-founder of Biodot, Inc. in 1994. Prior to this Dr. Tisone was President and co-founder of Cartesian Technologies, a genomics solutions company, and Executive Vice President and Board Member of Genomics Solutions.

Dr. Tisone was also President and one of the founders of Nouvas Manufacturing Technology Co., a custom automation engineering design company specializing in the development of equipment and instrumentation processing systems for use in the medical device and bio-diagnostic industries.

Along with being President of ASU R&D, Orange, CA (a division of ASU, AG), he also was the R&D Laboratory Director at their Electronics Research Laboratories in Rolling Meadows, IL. Being involved in the development of new quartz-based products for frequency control and measurement, the development of sensor technology and manufacturing automation, and the development of sensor and instrumentation products used to measure temperature and pressure in medical and industrial applications, Dr. Tisone brings a rich expertise to MatriCal.

Dr. Tisone holds a PhD degree in materials Science from Northwestern University and a B.S. degree in metallurgy from the Colorado School of Mines. He has published 42 papers and has been awarded 14 United States Patents.